ArticleGastro hep advances2025
Hepatocellular Carcinoma Among Patients With Metabolic Dysfunction Associated Steatotic Liver Disease.
Article in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the leading cause of cirrhosis and hepatocellular carcinoma (HCC). We decided to determine factors associated with cirrhosis and HCC among patients with MASLD in order to help develop a better HCC surveillance strategy. Methods: We retrieved Veterans Affairs data and identified patients with MASLD. Each patient with cirrhosis was propensity-matched to 3 patients without cirrhosis for age, sex, and race. The 2 groups were compared for demographics, clinical features, and comorbidities, and the incidence and factors associated with cirrhosis and HCC were determined. Results: Among 118,754 veterans noted to have MASLD, 74,475 were excluded. In the residual cohort of 44,279, 4844 patients had cirrhosis who were matched to 14,502 patients without cirrhosis. The median age was 61 years, 94% were men, and 62% were White. Patients with cirrhosis had higher body mass index, 45% had diabetes, and the majority had dyslipidemia and hypertension. The incidence rate of HCC in patients with cirrhosis was 9.9 per 1000 person-years, and among noncirrhotic patients, it was 0.3 per 1000 person-years. In the study cohort, age, male sex, and cirrhosis increased the likelihood of HCC, whereas Black race and pulmonary disease reduced the risk. Patients with cirrhosis had similar findings, whereas among those without cirrhosis, chronic kidney disease was associated with increased risk. Conclusion: Among patients with MASLD, advancing age, male sex, and cirrhosis were the dominant risk factors for HCC development. Similar associations were noted in patients with cirrhosis, whereas among those without cirrhosis, chronic kidney disease increased the likelihood of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.